Hematology & Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Renal Cell Carcinoma 73%
3. Therapeutics 46%
4. Non-Small Cell Lung Carcinoma 44%
5. Diphtheria Toxin 40%
6. Survival 37%
7. Immunotoxins 34%
8. Mutation 33%
9. palmitoyl-protein thioesterase 32%
10. Acute Myeloid Leukemia 31%
11. Proteins 31%
12. Lung Neoplasms 30%
13. Drug Therapy 30%
14. Nivolumab 27%
15. Breast Neoplasms 27%
16. Ricin 27%
17. Glioblastoma 26%
18. Genes 22%
19. Immunotherapy 21%
20. Brain Neoplasms 20%
21. Safety 20%
22. Neoplasm Metastasis 19%
23. Clinical Trials 18%
24. Radiotherapy 18%
25. Melanoma 18%
26. Progression-Free Survival 18%
27. Prostatic Neoplasms 18%
28. Leukemia 18%
29. Ceroid lipofuscinosis, neuronal 1, infantile 18%
30. anthrax toxin 17%
31. Pharmaceutical Preparations 17%
32. Cell Line 16%
33. Bone Marrow 16%
34. Growth 16%
35. Huntingtin Protein 15%
36. Glioma 15%
37. Sunitinib 15%
38. Neuronal Ceroid-Lipofuscinoses 15%
39. Granulocyte-Macrophage Colony-Stimulating Factor 15%
40. Enzymes 14%
41. ErbB Receptors 14%
42. Ipilimumab 14%
43. T-Lymphocytes 14%
44. Stem Cells 14%
45. Brain 13%
46. Colorectal Neoplasms 13%
47. Recurrence 12%
48. Liver 12%
49. In Vitro Techniques 12%
50. Blood Platelets 12%
51. Kidney Neoplasms 12%
52. Monoclonal Antibodies 12%
53. Graft vs Host Disease 12%
54. Antibodies 12%
55. Transplants 12%
56. Thrombosis 11%
57. Sickle Cell Anemia 11%
58. Interleukin-3 11%
59. Heterografts 11%
60. Isocitrate Dehydrogenase 11%
61. alpha-hydroxyglutarate 11%
62. Protein-Tyrosine Kinases 11%
63. DNA 11%
64. Adenocarcinoma 10%
65. Vascular Endothelial Growth Factor A 10%
66. Tissue Donors 10%
67. Pharmacokinetics 10%
68. Apoptosis 10%
69. Population 10%
70. Vitamin B 12 10%
71. Blood-Brain Barrier 10%
72. Bone Marrow Transplantation 10%
73. Interleukin-3 Receptors 10%
74. Lymphoma 10%
75. Confidence Intervals 10%
76. Small Cell Lung Carcinoma 10%
77. Multiple Myeloma 9%
78. Carcinogenesis 9%
79. Bevacizumab 9%
80. Kidney 9%
81. Fluorouracil 9%
82. Thrombocytopenia 9%
83. Biomarkers 9%
84. Barrett Esophagus 9%
85. Interleukin-2 9%
86. Lung 9%
87. Cisplatin 9%
88. Pancreatic Neoplasms 9%
89. Peptides 9%
90. Everolimus 8%
91. Radiation 8%
92. Hematologic Neoplasms 8%
93. Maximum Tolerated Dose 8%
94. Radiosurgery 8%
95. Docetaxel 8%
96. Erlotinib Hydrochloride 8%
97. Precursor Cell Lymphoblastic Leukemia-Lymphoma 8%
98. Ligands 8%
99. Serum 8%
100. Mechanistic Target of Rapamycin Complex 1 8%